Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alza Corp.

Division of Johnson & Johnson

Latest From Alza Corp.

Rigel Downsizes R&D To Ready Fostamatinib Commercial Effort

Biotech will cut 46 staff, mostly in research, including the entire antibody group, to focus on commercializing its Phase III thrombocytopenia candidate fostamatinib. Rigel adds industry vet Eldon Mayer to head up commercial team.

Immune Disorders Business Strategies

Spain's Ferrer To Rescue Floundering US Biotech Alexza

US Inhaled CNS drug biotech Alexza looks set to be acquired by Spain’s Ferrer, the licensee of its only marketed product Adasuve outside of the US, in an all-cash offer that includes contingent value rights.

Deals Platform Technologies

AcelRx’s Pain Drug Zalviso Delayed By Delivery Device Issues

FDA’s “complete response” letter asks the company to reduce the rate of optical errors and improve the instructions for use of the patient-activated, hand-held analgesic system.

BioPharmaceutical United States

Can “Novel-Novel” Drug Development Work? Deals Of The Week Considers Merck’s New Play

Partnering its PD-1-specific antibody candidate with three other companies, Merck indicates a new era may have arrived for testing novel agents in combination. Also, NIH partners with 10 biopharmas to transform the discovery model and Myriad moves to buy Crescendo.

BioPharmaceutical Business Strategies
See All

Company Information